Jade Biosciences (NASDAQ: JBIO) has 6.8% stake held by Bellevue

Rhea-AI Filing Summary

Bellevue Group AG, through its wholly owned subsidiary Bellevue Asset Management AG, reported a significant passive ownership stake in Jade Biosciences, Inc. common stock. They beneficially own 3,341,103 shares, representing 6.8% of the outstanding common stock, with shared voting and dispositive power over all of these shares.

The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Jade Biosciences. Bellevue and its subsidiary certify that the information provided is true, complete, and correct.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Jade Biosciences, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

008064206

(CUSIP Number)

12/16/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 008064206

1

Names of Reporting Persons

Bellevue Group AG

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,341,103.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,341,103.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,341,103.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

HC, CO

Comment for Type of Reporting Person: The percentage set forth in Row 11 is calculated based on 49,314,337 shares of Common Stock deemed outstanding.

SCHEDULE 13G

CUSIP No. 008064206

1

Names of Reporting Persons

Bellevue Asset Management AG

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SWITZERLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 3,341,103.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 3,341,103.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,341,103.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: The percentage set forth in Row 11 is calculated based on 49,314,337 shares of Common Stock deemed outstanding.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Jade Biosciences, Inc.
(b)	Address of issuer's principal executive offices: 221 CRESCENT ST., BUILDING 23, SUITE 105, WALTHAM, MA 02453
Item 2.
(a)	Name of person filing: Bellevue Group AG ("Bellevue") on behalf of its wholly-owned subsidiary, Bellevue Asset Management AG ("BAM AG")
(b)	Address or principal business office or, if none, residence: Bellevue: Theaterstrasse 12, Zurich, Switzerland, CH-8001 BAM AG: Theaterstrasse 12, Zurich, Switzerland, CH-8001
(c)	Citizenship: Bellevue: Switzerland BAM AG: Switzerland
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 008064206
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
	Swiss Financial Market Supervisory Authority (FINMA)
Item 4.	Ownership
(a)	Amount beneficially owned: 3,341,103
(b)	Percent of class: 6.8%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 3,341,103
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 3,341,103
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. This statement is filed jointly by Bellevue and BAM AG. BAM AG is a wholly-owned subsidiary of Bellevue.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Bellevue Group AG

Signature:	/s/ Stefano Montalbano
Name/Title:	Stefano Montalbano/ Chief Financial Officer
Date:	02/12/2026

Signature:	/s/ Christoph Eisenring
Name/Title:	Christoph Eisenring/ Head Legal & Compliance
Date:	02/12/2026

Bellevue Asset Management AG

Signature:	/s/ Christoph Eisenring
Name/Title:	Christoph Eisenring/ Head Legal & Compliance
Date:	02/12/2026

Signature:	/s/ Ivo Betschart
Name/Title:	Ivo Betschart/Chief Finance & Controlling
Date:	02/12/2026

FAQ

What ownership stake in JBIO does Bellevue Group report on this Schedule 13G?

Bellevue Group reports beneficial ownership of 3,341,103 shares of Jade Biosciences, Inc. common stock, representing 6.8% of the outstanding class. The filing shows Bellevue and its subsidiary share both voting and dispositive power over all of these reported shares.

Is Bellevue Group’s stake in Jade Biosciences (JBIO) a passive investment?

Yes. Bellevue certifies the securities were acquired and are held in the ordinary course of business as a passive investment. The filing states they were not acquired and are not held to change or influence control of Jade Biosciences, nor in connection with any such transaction.

Who are the reporting persons on the Jade Biosciences (JBIO) Schedule 13G?

The reporting persons are Bellevue Group AG and its wholly owned subsidiary, Bellevue Asset Management AG, both organized in Switzerland. The statement is filed jointly, reflecting their shared voting and dispositive power over the same block of Jade Biosciences common shares.

How many Jade Biosciences (JBIO) shares are used to calculate Bellevue’s 6.8% ownership?

The 6.8% ownership percentage is calculated based on 49,314,337 shares of Jade Biosciences common stock deemed outstanding. Bellevue’s 3,341,103 beneficially owned shares are measured against this total to determine their percentage interest in the class.

Does Bellevue Group have sole or shared voting power over its JBIO shares?

Bellevue reports no sole voting or dispositive power and instead has shared voting and shared dispositive power over all 3,341,103 Jade Biosciences shares. This means decisions on voting and disposition are made jointly under the structure described in the filing.

What regulatory status does Bellevue Asset Management claim in this JBIO filing?

The filing identifies Bellevue as a parent holding company or control person with its subsidiary Bellevue Asset Management AG. It notes classification under provisions for non-U.S. institutions regulated by the Swiss Financial Market Supervisory Authority (FINMA), supporting its eligibility to file on Schedule 13G.